Form 4: ResMed CEO Sells Shares for Tax Withholding

ResMed Inc.'s Chairman and CEO, Michael J. Farrell, disposed of 7,896.567 shares of common stock on November 11, 2025, to cover tax obligations related to the vesting of Restricted Stock Units.

Summary

• Michael J. Farrell, Chairman and CEO of ResMed Inc. (RMD), reported the disposition of 7,896.567 shares of ResMed Common Stock.
• The transactions occurred on November 11, 2025, at a price of $250.1 per share.
• The dispositions were made to the issuer for tax withholding purposes upon the vesting of Restricted Stock Units (RSUs).
• These RSUs were granted on three separate dates: November 16, 2022 (2,231.545 shares), November 16, 2023 (3,459.325 shares), and November 16, 2024 (2,205.697 shares).
• Following these transactions, Mr. Farrell directly beneficially owns 459,969 shares of ResMed Common Stock.
• Additionally, 2,090 shares are indirectly beneficially owned through the Lisette and Michael Farrell Family Trust.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction related to executive compensation and tax obligations. It does not indicate any fundamental change in the company's operations or outlook, thus warranting a neutral sentiment.

Positives

• The transactions represent the vesting of Restricted Stock Units, indicating that previously granted equity compensation to the CEO has matured and become exercisable.
• The disposition for tax withholding is a routine and expected event associated with equity compensation vesting, not a discretionary sale by the executive.

Negatives

• The disposition of shares, even for tax purposes, reduces the direct beneficial ownership of the CEO in the company's common stock.

Future Outlook

NA

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects standard executive compensation practices within publicly traded companies.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not a sale driven by a change in executive confidence or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine disposition of shares by the CEO for tax withholding purposes upon the vesting of Restricted Stock Units. Such transactions are common and expected as part of executive compensation and do not typically reflect a change in the company's fundamental performance or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'hold' stance is appropriate based solely on this filing.

Keywords

ResMed, RMD, Michael J. Farrell, Insider Transaction, Form 4, Tax Withholding, Restricted Stock Units, Equity Compensation, CEO